Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Uses of 20(s)-protopanaxadiol

A technology of protopanaxadiol and myocardial ischemia, applied in the application field of medicine, can solve the problems such as no report on myocardial protection effect, and achieve the effects of low cost, good activity and small side effects

Active Publication Date: 2015-12-09
SHANGHAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because the saponins of the diol group can be rapidly converted into various metabolites in the body after oral administration, including Rg3, Rh2, compound-K and PPD, these metabolites are significantly different from the saponins of the protopanaxadiol group in mechanism, and their myocardial protection The effect has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of 20(s)-protopanaxadiol
  • Uses of 20(s)-protopanaxadiol
  • Uses of 20(s)-protopanaxadiol

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0037] Experimental example 1: Effect on in vitro cultured cardiomyocytes treated with hydrogen peroxide

[0038] In order to investigate the cardioprotective function of metabolite 20(S)-protopanaxadiol saponin (PPD) of protopanaxadiol group saponins, this experiment selected the main diol group saponin Rb1 in the protopanaxadiol group saponin group to compare PPD and Rb1 protect cardiomyocytes treated with hydrogen peroxide in vitro.

[0039] 1. Test material

[0040] 1.1 Test samples: 20(S)-protopanaxadiol (PPD), Rb1 are provided by Shanghai Traditional Chinese Medicine Innovation Research Center;

[0041] 1.2 Experimental equipment:

[0042] Clean bench, Shanghai Dianshan Lake Purification Equipment Factory;

[0043] constant temperature CO 2 Incubator, American Forma company;

[0044] Enzyme-linked immunoassay instrument, American BioTek company;

[0045] Inverted biological microscope, Chongqing Optical Instrument;

[0046] Desktop constant temperature shaker, Tai...

experiment example 2

[0063] Experimental Example 2: Effects on Myocardial Ischemia and Ischemia-Reperfusion Injury Models

[0064] In order to further confirm the effect of 20(S)-protopanaxadiol on myocardial protection, the following example is a pharmacological and pharmacological study of 20(S)-protopanaxadiol on animal models of myocardial ischemia and ischemia-reperfusion injury.

[0065] 1. Test material

[0066] 1.1 Test samples

[0067] 20(S)-protopanaxadiol (PPD), provided by Shanghai Innovation Research Center of Traditional Chinese Medicine; prepare 20(S)-protopanaxadiol into a suspension according to the following method: Weigh 100mg sample, add 10ml 0.5% Grind CMC-Na and make a 10mg / ml suspension

[0068] 1.2 Positive control samples

[0069] Name: Nifedipine Tablets, provided by Shanghai Pharmaceutical (Group) Co., Ltd. Xinyi Pharmaceutical General Factory, specification: 10mg / tablet, batch number: Guoyao Zhunzi H31021222; properties: film-coated tablets; storage method: store at ...

Embodiment 1

[0145] Embodiment 1: The preparation method of 20(S)-protopanaxadiol

[0146] 1. Add 5.0 kg of notoginseng leaf glycosides, add n-butanol and sodium ethylate, put it into the reaction kettle, stir, feed oxygen, keep the bubbles in the bubbles continuously emerging, heat up, and react for 72 hours; add n-butanol after cooling down Saturated water was washed twice, the water layer was separated, n-butanol was concentrated under reduced pressure and recovered to dryness, n-butanol was recovered, the residue was stirred with water, extracted three times with ethyl acetate, the water layer was discarded, and the ethyl acetate layers were combined and used Wash twice with saturated saline, and remove the water layer;

[0147] 2. Add anhydrous sodium sulfate to the ethyl acetate layer, dry it, concentrate the ethyl acetate layer to dryness under reduced pressure, recover the ethyl acetate, and obtain the crude product of protopanaxadiol;

[0148] 3. Add ethyl acetate to the crude pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the new use of 20(S)-protopanaxadiol, specifically the application of 20(S)-protopanaxadiol in the preparation of drugs for the prevention and treatment of ischemic heart disease. 20(S)-Protopanaxadiol can reduce myocardial histological damage caused by ischemia and ischemia-reperfusion, reduce infarct size and enzymatic indicators related to myocardial necrosis, and reduce the J-point displacement of electrocardiogram.

Description

technical field [0001] The present invention relates to a new application of 20(S)-protopanaxadiol, in particular to the application of 20(S)-protopanaxadiol in the preparation of medicines for preventing and treating ischemic heart disease. Background technique [0002] In my country, cardiovascular disease (including hypertension and coronary heart disease) has become a major disease that endangers human health and life. In 2002, the mortality rate of heart disease among residents in big cities in my country was 75.68 per 100,000 people, ranking the third cause of death after malignant tumors and cerebrovascular accidents. [0003] Myocardial ischemic heart disease, also known as coronary heart disease (coronary heart disease), refers to the heart disease caused by myocardial ischemia or hypoxia due to coronary atherosclerosis narrowing or blocking the lumen. the most common type of . Clinical manifestations include stable angina, unstable angina, arrhythmia, and cardiog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/575A61P9/10
CPCA61K31/575A61P9/10
Inventor 许长江张文静潘欣萍汪沁琳杨子荣
Owner SHANGHAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com